Examining Cell Therapy in IPF: Harnessing ADCs & Leveraging Non-Cytotoxic TGF-β Payload to Selectively Target IPF & Reduce Toxicity
- Exploring the potential of ADCs to selectively deliver therapeutics while minimizing systemic toxicity
- Revaluating specific targeting of TGF-β in fibrosis by leveraging non-cytotoxic payloads to modulate TGF-β signaling without adverse effects
- Integrating ADCs with emerging approaches to enhance efficacy and safety in IPF treatment